These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay. Miura K; Perera S; Brockley S; Zhou H; Aebig JA; Moretz SE; Miller LH; Doumbo OK; Sagara I; Dicko A; Ellis RD; Long CA PLoS One; 2011; 6(6):e20947. PubMed ID: 21695140 [TBL] [Abstract][Full Text] [Related]
29. Process development and preclinical evaluation of a major Somanathan A; Mian SY; Chaddha K; Uchoi S; Bharti PK; Tandon R; Gaur D; Chauhan VS Front Immunol; 2022; 13():1005332. PubMed ID: 36211427 [No Abstract] [Full Text] [Related]
30. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. Miura K; Zhou H; Moretz SE; Diouf A; Thera MA; Dolo A; Doumbo O; Malkin E; Diemert D; Miller LH; Mullen GE; Long CA J Immunol; 2008 Dec; 181(12):8776-83. PubMed ID: 19050299 [TBL] [Abstract][Full Text] [Related]
32. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. Dutta S; Sullivan JS; Grady KK; Haynes JD; Komisar J; Batchelor AH; Soisson L; Diggs CL; Heppner DG; Lanar DE; Collins WE; Barnwell JW PLoS One; 2009 Dec; 4(12):e8138. PubMed ID: 19997632 [TBL] [Abstract][Full Text] [Related]
33. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Stowers AW; Kennedy MC; Keegan BP; Saul A; Long CA; Miller LH Infect Immun; 2002 Dec; 70(12):6961-7. PubMed ID: 12438375 [TBL] [Abstract][Full Text] [Related]
34. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374 [TBL] [Abstract][Full Text] [Related]
35. Neutralising antibodies block the function of Rh5/Ripr/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes. Healer J; Wong W; Thompson JK; He W; Birkinshaw RW; Miura K; Long CA; Soroka V; Søgaard TMM; Jørgensen T; de Jongh WA; Weir C; Svahn E; Czabotar PE; Tham WH; Mueller I; Barlow PN; Cowman AF Cell Microbiol; 2019 Jul; 21(7):e13030. PubMed ID: 30965383 [TBL] [Abstract][Full Text] [Related]
36. Specificity of the protective antibody response to apical membrane antigen 1. Hodder AN; Crewther PE; Anders RF Infect Immun; 2001 May; 69(5):3286-94. PubMed ID: 11292751 [TBL] [Abstract][Full Text] [Related]
37. Antibodies to malaria peptide mimics inhibit Plasmodium falciparum invasion of erythrocytes. Casey JL; Coley AM; Anders RF; Murphy VJ; Humberstone KS; Thomas AW; Foley M Infect Immun; 2004 Feb; 72(2):1126-34. PubMed ID: 14742560 [TBL] [Abstract][Full Text] [Related]
38. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate. Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771 [TBL] [Abstract][Full Text] [Related]
39. Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA. Favuzza P; Blaser S; Dreyer AM; Riccio G; Tamborrini M; Thoma R; Matile H; Pluschke G Malar J; 2016 Mar; 15():161. PubMed ID: 26979066 [TBL] [Abstract][Full Text] [Related]